The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
They’ve had six months to sort this cr*p out. Now they’ve adjourned YET AGAIN and it takes us past the delisting date. Dr K talks about a share price increase. How does that work if we’re not even in the market? Jam tomorrow? The day after? This year? Next year? Sometime? Never? All smoke and mirrors and the smell of rotten fish.
“Next few weeks!” So this is dragging on and on with no sign of a relisting . Isn’t the next few weeks going to be too late? Does this indeed conflict with what Dr K was telling us? He made it seem that everything would be more or less sorted at the next GM. I’m very dubious now.
This may have been posted before but it bears looking at. Not very complimentary to Sefton. Have those big names on Infotagion seen this I wonder?
https://www.*************.com/views/49132/iconic-labs-toxic-david-sefton-still-behind-the-scenes-pulling-strings-working-with-tory-mp-damian-collins
The fact that Dr Krebs has not responded to my polite enquiries regarding his assertion the FCA have been approached is making me very dubious. I think he is working on the inside but on who’s behalf? I still think this is a case for the financial press as well as the LSE.
Thank you Elfish and EUA.
Everybody get on it.
What say you Dr Krebs in response to what Elfish has to say about the FCA not being the right route? And I politely ask again, how do you know they have been approached and by whom?
Bloke goes into Gypsy Petulengro’s in Blackpool to have his palm read.
She peers closely at it and says “ I foresee a prosperous future and a very long life.”
“A very long life! That’s great”he beams. “Now can you tell me anything about Iconic Labs shares?”
“Yes. The General meeting went ahead today. Everything will be quickly resolved. The administrators will shortly issue a statement. The share will be relisted and you will make an absolute fortune.”
“Oh thank you!” he cried. Then dropped down dead.